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Carbon nanotubes for stabilization of
nanostructured lipid particles†
Nicholas P. Gaunt,a Yogita Patil-Sen,a Matthew J. Bakera,b and
Chandrashekhar V. Kulkarni*a
Carbon nanotubes (CNTs) are increasingly studied for innovative biotechnological applications particularly
where they are combined with essential biological materials like lipids. Lipids have been used earlier for
enhancing the dispersibility of CNTs in aqueous solutions. Here we report a novel application of CNTs for
stabilization of internally self-assembled nanostructured lipid particles of 2–5 μm size. Single-walled
(pristine) as well as –OH and –COOH functionalized multi-walled CNTs were employed to produce
nanostructured emulsions which stayed stable for months and could be re-dispersed after complete
dehydration. Concentrations of CNTs employed for stabilization were very low; moreover CNTs were
well-decorated with lipid molecules. These features contribute towards reducing their toxicity and
improving biocompatibility for biomedical and pharmaceutical applications. Our approach paves the
way for future development of combination therapies employing both CNTs and nanostructured lipid
self-assembly together as carriers of diﬀerent drugs.
Introduction
Carbon nanotubes (CNTs), owing to their special properties
such as small size and ability to bind with a broad range
of molecules, are exploited in many biomedical and pharma-
ceutical applications1–5 such as drug delivery,6,7 gene delivery,8
cancer therapy,6,9 medical imaging10 and tissue engineering
scaﬀolds.11 However, in vivo use of CNTs is still a task to be
accomplished due to their debatable toxicity issues;8 neverthe-
less some of the recent research in this direction is believed to
be promising.1,2,12 Although CNTs are yet to be approved by
FDA (Food and Drug Administration) for safe use in humans,
their pre-clinical applications as biomaterials have been extre-
mely eﬀective.12 Many studies performed on animal models
endorse CNTs being safe for living organisms provided that
they are functionalized properly and more importantly, the
method and site of use are appropriate.12 The functionali-
zation is very important aspect in determining the biological
toxicity of CNTs in almost all of the aforementioned appli-
cations, for which the CNT surface needs to be modified by
non-covalent or covalent interactions using various molecules
like e.g. lipids, proteins, surfactants, drugs, polymers, pep-
tides, nucleic acids and metal nanoparticles. Some of these
molecules not only interact but also self-organize on CNT sur-
faces.13,14 Amphiphilic molecules, like lipids, are among such
molecules which form self-assembled nanostructures when in
solvents.15 However, with CNTs they self-organize in such a
way that the non-polar part is shielded from polar medium via
hydrophobic interactions with CNT surface while the hydro-
philic part faces polar solvent medium, which is usually water
based.10,13,16–20
The type of self-assembled nanostructure, also called liquid
crystalline lipid phases interacting with carbon nanotubes
could diﬀer from lipid to lipid21 as well as with physicochemi-
cal conditions.22 Usually the lamellar nanostructure (Fig. 1) is
most commonly observed which mimics plasma membrane
whereas hexagonal and cubic types of nanostructures resemble
complex intracellular biomembranes.15,23 Lipid nanostructures
are also used for many applications, for example, for separ-
ation of biomolecules,24 protein crystallization,25 synthesis of
metal nanoparticles26 and electrophoresis gels for amphiphilic
molecules.24 However, in some cases their applicability is ham-
pered by their extremely high viscosity and inconsistent
domain consistency. These problems are resolved by disper-
sing them into submicron (typical diameter 200–400 nm) or
micron sized colloidal particles with large quantities of water
(about 80–95%).27,28 The process involves kinetic stabilization
of lipid nanostructures using some energy input and stabilizer
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molecules like surfactants, polymers, hydrocolloids or bio-
molecules resulting into oil-in-water (O/W) emulsions.28,29
(Note: Here ‘oil’ phase refers to lipid chains region.) The origi-
nal lipid self-assembly is usually preserved inside dispersed
particles and the overall viscosity is reduced by a few orders of
magnitudes thereby enhancing their applicability.29,30 Major
application of internally self-assembled lipid particles is for
‘drug delivery’ because of the possibility of loading them with
hydrophilic, hydrophobic and amphiphilic molecules.31–33
In this work we exploit CNTs as novel stabilizers for nano-
structured lipid particles as depicted in Fig. 1. Use of CNTs is
expected to be significantly advantageous in stabilization of
such systems because of their unique surface properties that
facilitate extensive functionalization. Presence of lipid also
overcame the destabilization of CNTs in aqueous solution
which was otherwise occurring in minutes after their dis-
persion without lipid molecules. As mentioned earlier, CNTs
themselves are promising candidates for drug delivery and
other biomedical applications.12 Combining them with nano-
structured lipid particles that could be also loaded with drugs
may open up many new pathways for example, for combination
therapy or polytherapy i.e. for delivering multiple drugs or a
drug and other inhibitory molecules at the same time at the
same target. Such therapies are required mainly against multi-
drug resisting macromolecules or pathogens.34,35 The concen-
tration of CNTs required to stabilize an emulsion (per unit
volume of water) is extremely low (as low as 0.3 μg ml−1).
Furthermore, the biocompatibility of CNTs is expected to be
greatly enhanced due to decoration with lipid molecules.
These features can be attributed to a very low to negligible
in vivo toxicity of CNT stabilized lipid nanoparticles for bio-
medical and pharmaceutical applications.
Results and discussion
Preparation of CNT-stabilized nanostructured lipid particles
Powdered forms of –COOH functionalized multi-walled (MW)
CNTS, –OH functionalized MWCNTs and pristine single-
walled (SW) CNTs were pre-dispersed in water by probe ultra-
sonicator followed by addition of molten Dimodan U (DU).
The DU is a commercial lipid mainly consisting of monoglycer-
ides and it forms a bicontinuous cubic Pn3m phase (crystallo-
graphic space group 224) in excess water (at room
temperature).36 The Pn3m phase exhibits 3-dimensionally
folded curved bilayer draped over double diamond type mathe-
matical minimal surface15 separating two continuous water
networks (Fig. 1A). The ‘bicontinuous’ feature of this nano-
structure facilitates reconstitution and practically uninterrupted
diﬀusion of amphiphilic molecules like membrane proteins
providing them native like environment.37 Each DU-CNT
mixture in water was subjected to further ultrasonication in
order to break large and inconsistent lipid domains formed
during the hydration of a lipid. Dispersing the bulk lipid in
this manner apparently speeds up the process of lipid
hydration and thus equilibrium formation of self-assembled
nanostructures, which otherwise requires considerably long
time (could be one or many days) and/or freeze-thaw cycling.
While the bulk lipid phase breaks into particles, the lipid
coated CNTs are presumed to form a shell around them
(Fig. 1B). The interfacial stabilization avoids further aggrega-
tion of both, nanostructured lipid particles as well as CNTs.
Such kinetic stabilization can be called a Pickering38 (due to
the use of solid particles) emulsion of oil-in-water (O/W) type,
where lipid forms an ‘oil phase’ while ‘excess water’ forms a
continuous emulsion medium.28 Such an aqueous medium
Fig. 1 CNT Stabilized Internally Self-assembled Lipid Particles. (A) In presence of water, amphiphilic lipid molecules self-assemble into various
liquid crystalline phases such as lamellar and cubic nanostructures. (B) Highly viscous lipid phases like cubic nanostructures are kinetically stabilized
(using ultrasound energy and CNT stabilizer) into ﬂuid dispersion. Pristine single-walled (SW) and functionalized (–OH and –COOH) multi-walled
(MW) CNTs were used to stabilize the oil-in-water (Pickering) emulsion.
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and the hydrophobic lipid core of similar lipid particles (stabil-
ized by surfactants) are shown to provide right environments
for incorporation of hydrophilic and hydrophobic active
pharmaceutical agents, respectively.32,33 Moreover, the amphi-
philic lipid bilayer fabricating the cubic nanostructure is
useful for reconstitution of membrane proteins.39,40 Dynamic
light scattering studies confirmed that CNT stabilized nano-
structured lipid particles were comparable in size (2–5 μm)
with those stabilized by conventional surfactant stabilizer-
pluronic F127 (Fig. 2).
Lipid decoration on CNTs revealed by Raman spectroscopy
Raman spectroscopy revealed CNT–lipid interactions respon-
sible for their mutual stabilization in aqueous solutions
(Fig. 3). The CNT spectra contain typical Raman graphite
bands; the G band is assigned to the in-plane vibration of ‘C–C
bond’, the D band (not shown) is activated by the presence of
disorder in carbon systems and the G′ band attributed to the
overtone of the D band.41 Upon interaction and formation of
CNT stabilized lipid particles the G and G′ bands display a
blue shift (shift to higher wavenumbers). Table 1 lists the peak
centers for characteristic bands from pure CNTs and nano-
structured lipid particles containing CNTs. A blue shift, in
case of CNTs, is a result of either or a combination of the fol-
lowing: (1) the dispersion of CNTs, as opposed to a bundled
state when pure41 (2) coating of CNTs; Douroumis et al.42 have
shown significant blue shifts when analysing lipid coated
SWCNTs and suggest that the presence of functionality aﬀects
the symmetric radial vibrations of the hollow cylinders
through stiﬀening which are attributed to the interactions
between the CNTs and the lipid molecules (3) subjecting CNTs
to a high pressure.43
Significant blue shifts (Table 1) observed in all spectra of
lipid nanoparticles containing CNTs provide an evidence for
‘dispersed’ rather than ‘bundled’ CNTs. Hydrophobic inter-
actions between CNT surface and alkyl chains of lipid mole-
cules further contribute to the blue shift. Moreover, CNTs are
exerted with a greater pressure due to increase in the overall
viscosity of lipid particles because of dehydration. Decrease in
relative intensities of typical CNT bands (as compared to
uncoated CNTs) and emergence of prominent lipid signals
also prove the fact that CNTs were decorated with lipid
molecules.
Fig. 3 Raman spectra elucidating lipid decoration on CNTs. Raman
spectra of (A) pure lipid, MWCNT-COOH and CNT stabilized lipid nano-
particles containing 5.0 μg ml−1 MWCNT-COOH, (B) pure lipid, –OH
functionalized multi-walled carbon nanotubes (MWCNT-OH) and lipid
nanoparticles containing 5.0 μg ml−1 MWCNT-OH, and (C) pure lipid,
single-walled carbon nanotubes (SWNT) and lipid nanoparticles contain-
ing 0.3125 μg ml−1 SWCNT (Other concentrations’ Raman spectra are
shown in ESI Fig. S1). All curves represent an average of ten spectra
where intensities, in arbitrary units (labels not shown) are plotted along
y-axis. Blue shift in typical G and G’ bands of CNTs represent the inter-
action between CNT surface and lipid molecules. Lipid decoration over
CNTs was also depicted by decrease in relative intensities of CNT peaks
and appearance of lipid signals which are visible from blue curves.
Dashed (G band) and dotted (G’ band) lines are used to guide the eyes.
(D) Schematic diagram of lipid self-assembling on CNT surface. Alkyl
chains of lipid molecules interact with hydrophobic CNT surface
whereas the hydrophilic lipid headgroups face aqueous region. Interior
of particles is ﬁlled with self-assembled lipid nanostructure as indicated
by the cross section of lipid particle (yellow).
Table 1 Raman wavenumbers and shift for CNTs and nanostructured
lipid particles with CNTs
CNT type
Peak centre
of CNT (cm−1)
Peak centre
of CNT–lipid
nanostructure
(cm−1)
Wavenumber
shifted (cm−1)
MWCNT-COOH 1578.23 (G) 1600.05 21.83
2683.72 (G’) 2720.08 36.36
MWCNT-OH 1570.91 (G) 1588.24 17.33
2687.27 (G’) 2698.18 10.91
Pristine SWCNT 1570.91 (G) 1585.45 15.44
Fig. 2 Particle size of nanostructured lipid particles. (A) An average par-
ticle size of CNT stabilized nanostructured lipid particles was in the
range of 2–5 μm and it was comparable to the size of lipid particles
stabilized by pluronic F127 surfactant (B), as determined from dynamic
light scattering experiments. An additional peak for surfactant based
system could be attributed to surfactant micelles of about 100 nm size.
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Optimum CNT : lipid ratio and stability of nanostructured
lipid particles
As discussed earlier, interface of lipid particles is stabilized by
a layer of CNTs enclosing self-assembled nanostructures at the
core. However, we observed that there is a particular range of
CNT : lipid ratio in which they result in stable emulsions;
ratios higher than this cause aggregation of CNTs as shown in
Fig. 4 (arrows indicate visible aggregates of excess CNTs). Simi-
larly lower ratios do not lead to stable emulsions because of an
insuﬃcient number of CNTs in the solution. Best working con-
centrations for MWCNT-COOH and MWCNT-OH were found
to be between 3 to 5 μg ml−1 whereas for SWCNT they were in
the range of 0.3–0.45 μg ml−1. Previous research on the toxicity
of pristine MWCNTs demonstrates that 40 μg ml−1 dosage
should have no toxicity on human T lymphocytes,44 while the
research on pristine SWCNTs states that 7.5 μg ml−1 dosage
causes only 10% decrease in cell proliferation and activity in
Mesothelioma cell line MSTO-211H.45 CNT concentrations
employed for stabilizing nanostructured lipid particles, in this
work are well below (by an order of magnitude) these toxicity
limits. Moreover, the functionalization (in case of MWCNTs)
and coating with lipid molecules are expected to enhance bio-
compatibility and reduce the likelihood of a toxic eﬀect.
We were able to stabilize as low as 2% dispersed phase
emulsions using the same lipid : CNTs ratio (Fig. 5A) used for
preparing all above emulsions (5% dispersed phase). To
another end, emulsions up to 20% lipid material were also pre-
pared by maintaining CNT : lipid ratio constant (Fig. 5A). This
wide range of nanostructured lipid particle concentrations
facilitates their loading with extensively varied quantities of
drug molecules. CNT stabilized emulsions were stable for
about 2 months after which CNTs start aggregating, but they
were well dispersed again with only gentle shaking (Fig. 5B).
Emulsions were also capable of retaining their stability after
complete dehydration via freeze-drying followed by rehydration
(Fig. 5C). The dehydrated lipid nanoparticles exhibited lamel-
lar nanostructure similar to the dry lipid at ambient tempera-
tures (see small angles X-ray scattering patterns in ESI
Fig. S2†).
Experimental
Materials
Single-walled carbon nanotubes (SWCNT) and multi-walled
carbon nanotubes with –OH functionalization (MWCNT-OH)
were obtained from Nanoamor (Houston, USA) whereas
–COOH functionalized multi-walled CNTs (MWCNT-COOH)
were purchased from Sigma-Aldrich (Athens, Greece). The
lipid, Dimodan U/J (DU) was a generous gift from Danisco
(Brabrand, Denmark). DU is a low-cost commercial product, as
compared to its pure lipid analogues, containing more than
98% mono-glycerides. The triblock copolymer pluronic F127
(PEO99-PPO67-PEO99) was purchased from Sigma-Aldrich, UK.
All solutions were prepared with Millipore water.
Fig. 4 Optimum CNT concentrations for stable emulsions. Stable
emulsions (shown by purple shade) were obtained in the region of
3.0–5.0 μg ml−1 for MWCNT–OH as in (A) and MWCNT–COOH as in (B).
The concentration of SWCNTs for stable emulsions as in (C) was about
an order of magnitude less than above numbers. It was also possible to
get stable emulsions at concentrations very near to these ranges (as
indicated by color gradient). For lower concentrations of CNTs, large
domains of lipid were seen as there were too little CNTs per lipid
whereas for higher concentrations there were too many CNTs which
tend to aggregate; some of these are indicated by black arrows.
Fig. 5 Stability and regeneration of lipid particulate emulsions. (A) Con-
centration of dispersed phase, mainly lipid could be tuned from 2% to
20%. At 20% the emulsions become thick due to higher lipid material
above which it was hard to prepare them using the ultrasonication
method. (B) CNT stabilized nanoparticulate emulsions were stable for
about 2 months, after which a few CNT aggregates were observed. It
was, however possible to re-disperse them merely upon gentle shaking.
(C) Emulsions could be completely dehydrated and dispersed again.
There was a little foam on the top of re-dispersed emulsion which
settled in about 2 days resulting into the stable emulsion. Above studies
correspondingly demonstrate interesting properties of CNT stabilized
emulsions as, capability of uptaking higher quantities of functional
material (e.g. active molecules like drugs), shelf-life and practicability of
storage/transport.
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Preparation of nanostructured lipid particles
First, powdered CNTs (MWCNT-OH, MWCNT-COOH and
SWCNT) were dispersed in 100 ml water using probe ultra-
sonicator (ULT065 from Ultrawave, Cardiﬀ, UK) at 40% power
for 2 minutes without pulse. CNTs were stable on their
own (without lipid) during preparation time (for about
20 minutes). The solution of surfactant F127 was prepared by
simply stirring 200 mg of surfactant in 100 ml water. 9.5 ml of
each of above solutions was then added to 500 mg of molten
DU in a glass vial. The mixtures were then subjected to ultra-
sonication with same parameters as CNT dispersions. Emul-
sions were allowed to cool down (about 10 minutes) prior to
further use.
Particle size measurement using dynamic light scattering
Particle sizes in dispersions were determined by using the
Zetasizer Nano-ZS dynamic light scattering (DLS) equipment
(from Malvern Instruments, UK). The data, in the form of par-
ticle size distribution was analyzed using Malvern DTS version
5.0. Each sample was tested 10 times and 5 such repeats were
performed to get final plots.
Raman spectroscopy on lipid–CNT samples
CNT, lipid and CNT–lipid samples were dehydrated using
nitrogen gas followed by vacuum drying in the desiccator for
about 20 minutes. Spectroscopic measurements were carried
out on a Horiba Jobin-Yvon LabRAM HR800 spectrometer.
A 532 nm laser was utilized to collect spectra from
100–4000 cm−1 using a grating of 600 g mm−1 and blazed at
750 nm. Spectra were acquired using ×50 long working dis-
tance objective with a numerical aperture of 0.50. The confocal
hole was set at 100 μm for spectral collections. The detector
used was an Andor electromagnet (EM) charged coupled
device (CCD). A video camera with the Raman system was used
to guide spectral collection. All spectra were collected with
sample situation on Calcium Fluoride slides (Crystran, UK).
The instrumentation was calibrated before operation to silicon
at the spectral line of 520.8 cm−1. Spectra were acquired using
the 532 nm laser at 1% exposure for 10 seconds and accumu-
lated 5 times. Immediate data interrogation and manipulation
was carried out on the raw data using the LabSpec 6 spectro-
scopy software suite (HORIBA Scientific).
Conclusions and perspectives
To conclude, we were able to produce nanostructured lipid par-
ticles with internal self-assembly using various CNTs as emul-
sion stabilizers. In the past, there have been several studies on
using lipids or surfactants for dispersion and functionalization
of CNTs, however this is the first report showing a range of
CNTs for stabilization of lipid based emulsions. Requirement
of very low levels of CNTs is promising for in vivo applications
as the amount of CNTs administered into the body is an order
of magnitude below toxicity limits revealed by the current lite-
rature, in addition, the biocompatibility of CNTs is greatly
improved due to their coating with lipid molecules. Further-
more, owing to the possibility of loading functional molecules
within lipid self-assembly as well as on CNT surface, the CNT
stabilized lipid particles exhibit an enormous potential in
emerging areas of pharmaceutical and biomedical sciences
with special relevance to the development of combination
therapies against major diseases. Fundamental properties of
these emulsions are that they exhibit good kinetic stability;
moreover, they can be regenerated after total dehydration of
constituents. This allows for easy storage and transport of
stabilized emulsions for use in harsh environments such as
developing countries or forward based military hospitals.
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